Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's OVERALL BUDGET FOR FISCAL 1989 TOTALS $520 MIL

Executive Summary

FDA's OVERALL BUDGET FOR FISCAL 1989 TOTALS $520 MIL. under a tentative plan drafted by the Office of Management & Budget and described in Jan. 6 budget documents. An OMB proposal of $520 mil. for the year would be $43 mil. higher than 1988 appropriations of $477 mil. and $33 mil. (6.8%) more than the $487 mil. (102% of the 1988 figure) provided for 1989 by the Budget Reconcsiliation Act, which passed Dec. 22. The budget "passback" document contains OMB's decisions on the shape of the Administration's budget proposal for fiscal 1989, and it constitutes a review of requests by each agency of each federal department. FDA Commissioner Young, HHS Secretary Bowen and other agency and department heads may appeal the numbers in OMB's passback. After an appeal, OMB will incorporate any changes into President Reagan's proposed budget, to be submitted to Congress in mid-February. OMB has dropped its user fee proposal. The document states that "OMB dropped the proposal to offset budget authority through collections of user fees for reviewing new product applications." The Administration proposed a user fee program in its previous five budget requests, but authorizing legislation never found a champion in Congress. Overall, HHS would ask Congress for a fiscal 1989 budget of $12.5 bil., under the passback. The total represents a 5% increase over the department's 1988 funding level. A major factor in the increase is "continued emphasis in prevention, treatment, and outreach activities related to AIDS," the document states. Departmental funding for AIDS-related activities would total $1.3 bil., an increase of 37% over the fiscal 1988 appropriation. An FDA request for viral laboratory construction is "not explicitly provided for" in the passback. However, the document states, $25 mil. is provided for "AIDS construction" in Bethesda using an account that consolidates AIDS-related funding for all agencies. OMB is proposing to hold FDA manpower at a reduced rate through fiscal 1988 and 1989. Actual agency full-time equivalents at the end of 1987 totaled 7,151, the document states. OMB's target for 1988 and 1989 was 7,069 and HHS's request was 7,069 for 1988 and 7,316 for 1989-1993. However, OMB has established an "allowance" of 7,054 FTEs for 1988-1993.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS013004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel